Protein-Protein Interaction Modulator
Protein-protein interaction modulators are compounds that influence the interaction between proteins, either by enhancing or disrupting their binding. These modulators are valuable tools in studying protein networks, understanding disease mechanisms, and developing new therapeutic strategies. Protein-protein interactions are fundamental to many biological processes, including signal transduction, immune response, and cellular regulation. At CymitQuimica, we offer a diverse range of high-quality protein-protein interaction modulators to support your research in biochemistry, molecular biology, and drug discovery.
Found 63 products of "Protein-Protein Interaction Modulator"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
AMG 510
CAS:<p>KRAS G12C inhibitor</p>Formula:C30H30F2N6O3Purity:(%) Min. 98%Color and Shape:PowderMolecular weight:560.59 g/molCBR 470-1
CAS:<p>Activates NRF2 signalling</p>Formula:C14H20ClNO4S2Purity:Min. 95%Color and Shape:PowderMolecular weight:365.9 g/molBT 18
CAS:<p>Activator of RET signalling cascade and a derivative of a GFL mimetic compound BT 13. Molecular docking calculations and molecular dynamics simulations were performed in GDNF−GFRα1−RetA complex and showed that BT 18 binds to the allosteric site in GFRα1 as well as RetA surface interfacing GFRα1.</p>Formula:C30H31F4N3O6SPurity:Min. 95%Color and Shape:SolidMolecular weight:637.64 g/molCCG 63808
CAS:<p>Reversible inhibitor of RGS proteins</p>Formula:C25H15FN4O2SPurity:Min. 95%Molecular weight:454.08998(2R)-Arimoclomol maleate
CAS:<p>(2R)-Arimoclomol maleate is an investigational pharmaceutical compound, which is an orally bioavailable small molecule with pharmacological activity primarily targeting cellular protein homeostasis mechanisms. This therapeutic agent is derived from molecular chaperones and operates by selectively enhancing the expression of heat shock proteins (HSPs). The mechanism of action involves the modulation of the heat shock response, wherein (2R)-Arimoclomol maleate amplifies the natural cellular defense pathways against protein misfolding and aggregation.</p>Formula:C18H24ClN3O7Purity:Min. 98 Area-%Color and Shape:White PowderMolecular weight:429.85 g/molBardoxolone methyl
CAS:<p>Activater of the Nrf2 pathway and an inhibitor of the NF-κB pathway. Possible applications have extended to anti-viral treatment of COVID-19.</p>Formula:C32H43NO4Purity:Min. 95%Color and Shape:White PowderMolecular weight:505.69 g/molH 151
CAS:<p>A potent inhibitor of STING protein (stimulator of interferon genes), a protein that partakes in intracellular DNA sensing pathway. H 151 blocks palmitoylation of STING, which is required for the formation of multimeric complexes for recruiting downstream signalling molecules. Inhibition of STING by H 151 reduces pro-inflammatory cytokine synthesis.</p>Formula:C17H17N3OPurity:Min. 95%Color and Shape:SolidMolecular weight:279.34 g/molCytochalasin D
CAS:<p>Inhibits actin polymerization</p>Formula:C30H37NO6Purity:Min. 95%Color and Shape:PowderMolecular weight:507.62 g/molAMG 510 racemate
CAS:<p>Racemic mixture of AMG 510</p>Formula:C30H30F2N6O3Purity:Min. 95%Color and Shape:PowderMolecular weight:560.59 g/molNL 1
CAS:<p>Inhibits the mitochondrial outer mebrane protein mitoNEET, anti-leukaemic</p>Formula:C18H25NO3SPurity:Min. 95%Color and Shape:SolidMolecular weight:335.46 g/molLF3
CAS:<p>A potent inhibitor of Wnt/β-catenin signalling pathway that interferes with β-catenin/TFC4 interaction. Reduces growth and motility of colon cancer cells. Inhibits self-renewal, whilst inducing differentiation in cancer stem cells.</p>Formula:C20H24N4O2S2Purity:Min. 95%Color and Shape:PowderMolecular weight:416.56 g/molDocetaxel - Bio-X ™
CAS:<p>Docetaxel is an antineoplastic agent that is used to treat various cancers such as breast and prostate cancer. This drug interferes with the normal function of microtubule growth. It is an anti-mitotic drug used in chemotherapy. Research has shown that this drug also induces programmed cell death in cancer cells.</p>Formula:C43H53NO14Purity:Min. 90 Area-%Color and Shape:White/Off-White SolidMolecular weight:807.88 g/molNAcM-OPT
CAS:<p>Inhibits N-Acetyl-mediated interaction between BE2M (E2 conjugating enzyme) and DCN1 (a component of E3 ligase complex). Also has inhibitory action on DCN2 and NEDD8 ubiquitin-like protein. Reduces anchorage-independent growth in DCN1-amplified cell line.</p>Formula:C23H29Cl2N3OPurity:Min. 95%Color and Shape:solid.Molecular weight:434.4 g/molAutogramin 2
<p>Autophagy inhibitor that selectively targets the StART domain of GRAMD1A</p>Formula:C21H27N3O4SPurity:Min. 95%Color and Shape:SolidMolecular weight:417.52 g/molABBV 075
CAS:<p>Inhibitor of BET bromodomain; antineoplastic</p>Formula:C22H19F2N3O4SPurity:Min. 95%Color and Shape:SolidMolecular weight:459.47 g/molGNE 371
CAS:<p>A chemical probe for the dual bromodomains of human transcription-initiation-factor TFIID subunit 1 (TAF1). GNE 371 binds TAF1 with an IC50 of 10 nM and is selective over other bromodomain family members. Exerts anti-proliferative effects in synergy with BET inhibitor JQ1.</p>Formula:C24H25N5O3Purity:(Hplc-Ms) Min. 98 Area-%Molecular weight:431.49 g/molES9-17
CAS:<p>Inhibitor of clathrin-mediated endocytosis (CME) and ligand to the clathrin heavy chain (CHC). ES9-17 is an inhibitor of the CHC function with EC50 of 13 μM in plant model Arabidopsis thaliana. ES9-17 is a non-protonophoric CME inhibitor and it does not alter the cytoplasmic pH levels substantially. In a mammalian cell line HeLa, ES9-17 reduced the uptake of transferrin, which is a CME-driven process.</p>Formula:C10H8BrNO2S2Purity:Min. 95%Color and Shape:Off-White PowderMolecular weight:318.21 g/mol17-Allylaminogeldanamycin
CAS:<p>17-AAG is the first clinically tested hsp90 inhibitor that exhibits antitumor activity. Its antitumor effects are documented in vivo for various animal models, including erbB2-dependent breast cancer, prostate cancer models, and melanoma.</p>Formula:C31H43N3O8Purity:Min. 95%Color and Shape:PowderMolecular weight:585.69 g/molEED 226 monohydrate
CAS:<p>Potent and selective inhibitor of polycomb repressive complex 2 (PRC2), by binding to the K27me3-pocket of the regulatory EED subunit. Inhibits H3K27 methylation in histone 3. Has anti-tumor activity in murine xenograft models. Synergistic with EZH2 inhibitor against cancer cell growth.</p>Formula:C17H15N5O3S·H2OPurity:Min. 95%Color and Shape:White To Yellow SolidMolecular weight:387.41 g/molAPTO 253
CAS:<p>Induces Kruppel like factor 4 (KLF4) and reduces the expression of MYC. Anti-tumor activity of APTO 253 has been demonstrated in AML and haematological malignancies. Inducing KLP4 expression in ovarian cancer cells using APT0 253 sensitises cells to cisplatin and paclitaxel. BRCA1/2-deficient cancer cells are hypersensitive to APTO 253, which mediates its action by causing DNA damage.</p>Formula:C22H14FN5Purity:Min. 95%Color and Shape:SolidMolecular weight:367.38 g/mol
